Publicaciones en las que colabora con M. E. Alonso Sarasquete (19)

2023

  1. Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

    International Journal of Molecular Sciences, Vol. 24, Núm. 10

2021

  1. Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival

    International Journal of Cancer, Vol. 148, Núm. 8, pp. 1887-1894

  2. Genetically determined telomere length and multiple myeloma risk and outcome

    Blood Cancer Journal, Vol. 11, Núm. 4

2020

  1. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  2. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Identification of miRSNPs associated with the risk of multiple myeloma

    International Journal of Cancer, Vol. 140, Núm. 3, pp. 526-534

  3. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

2015

  1. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

  2. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies

    Haematologica, Vol. 99, Núm. 8, pp. 1365-1372

2013

  1. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study

    British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589

  2. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

2012

  1. Genomic analysis of high-risk smoldering multiple myeloma

    Haematologica, Vol. 97, Núm. 9, pp. 1439-1443

2008

  1. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytoehrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis

    Blood, Vol. 112, Núm. 7, pp. 2709-2712

  2. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response

    British Journal of Haematology, Vol. 142, Núm. 5, pp. 766-774

  3. The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease

    Tissue Antigens, Vol. 71, Núm. 6, pp. 548-551

2006

  1. Application of self-quenched JH consensus primers for real-time quantitative of PCR of IGH gene to minimal residual disease evaluation in multiple myeloma

    Journal of Molecular Diagnostics, Vol. 8, Núm. 3, pp. 364-370

2005

  1. Minimal residual disease monitoring in multiple myeloma: A comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry

    Haematologica, Vol. 90, Núm. 10, pp. 1365-1372